Cargando…

2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道

Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and t...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051303/
https://www.ncbi.nlm.nih.gov/pubmed/35477193
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.10
_version_ 1784696522727751680
collection PubMed
description Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes.
format Online
Article
Text
id pubmed-9051303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-90513032022-05-11 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道 Zhongguo Fei Ai Za Zhi 病例报道 Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes. 中国肺癌杂志编辑部 2022-04-20 /pmc/articles/PMC9051303/ /pubmed/35477193 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.10 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 病例报道
2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
title 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
title_full 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
title_fullStr 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
title_full_unstemmed 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
title_short 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
title_sort 2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
topic 病例报道
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051303/
https://www.ncbi.nlm.nih.gov/pubmed/35477193
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.10
work_keys_str_mv AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào
AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào
AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào
AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào
AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào
AT 2lìmiǎnyìjiǎnchádiǎnyìzhìjìliánhéhuàliáoyǐnfā2xíngtángniàobìnggèànbàodào